Sfoglia per Autore
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
2024 Colombo, N; Lorusso, D; Monk, B; Slomovitz, B; Hasegawa, K; Nogueira-Rodrigues, A; Zale, M; Okpara, C; Barresi, G; Mckenzie, J; Makker, V
Reply to P.-H. Luo et al
2024 Monk, B; Colombo, N; Tewari, K; Tekin, C; Keefe, S; Lorusso, D
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial
2024 Tewari, K; Colombo, N; Monk, B; Dubot, C; Cáceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüs, M; Olivera Hurtado de Mendoza, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Tekin, C; Li, K; Toker, S; Keefe, S; Lorusso, D
Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins
2024 Caldarelli, M; Rezzi, S; Colombo, N; Pirali, T; Papeo, G
Letter to the editor-The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible?
2024 Betella, I; De Vitis, L; Calidona, C; Multinu, F; Colombo, N
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2024 Oaknin, A; Gladieff, L; Martínez-García, J; Villacampa, G; Takekuma, M; De Giorgi, U; Lindemann, K; Woelber, L; Colombo, N; Duska, L; Leary, A; Godoy-Ortiz, A; Nishio, S; Angelergues, A; Rubio, M; Fariñas-Madrid, L; Yamaguchi, S; Lorusso, D; Ray-Coquard, I; Manso, L; Joly, F; Alarcón, J; Follana, P; Romero, I; Lebreton, C; Pérez-Fidalgo, J; Yunokawa, M; Dahlstrand, H; D'Hondt, V; Randall, L
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
2024 Boidot, R; Blum, M; Wissler, M; Gottin, C; Ruzicka, J; Chevrier, S; Delhomme, T; Audoux, J; Jeanniard, A; Just, P; Harter, P; Pignata, S; Gonzalez-Martin, A; Marth, C; Maenpaa, J; Colombo, N; Vergote, I; Fujiwara, K; Duforet-Frebourg, N; Bertrand, D; Philippe, N; Ray-Coquard, I; Pujade-Lauraine, E
Reply to Z.R. McCaw et al
2023 Matulonis, U; Lorusso, D; Oaknin, A; Pignata, S; Dean, A; Denys, H; Colombo, N; Van Gorp, T; Konner, J; Marin, M; Harter, P; Murphy, C; Wang, J; Noble, E; Esteves, B; Method, M; Coleman, R
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix
2023 Valenza, C; Spada, F; Multinu, F; Benini, L; Borghesani, M; Algeri, L; Rubino, M; Pisa, E; Gervaso, L; Cella, C; Carinelli, S; Bruni, S; Schivardi, G; Curigliano, G; Zanagnolo, V; Aletti, G; Colombo, N; Fazio, N
Myeloid neoplasms post PARP inhibitors for ovarian cancer
2023 Caruso, G; Gigli, F; Parma, G; Lapresa, M; Derio, S; Palaia, I; Colombo, N
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
2023 Disilvestro, P; Banerjee, S; Colombo, N; Scambia, G; Kim, B; Oaknin, A; Friedlander, M; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G; Gourley, C; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Mathews, C; Liu, J; Mcnamara, J; Lowe, E; Ah-See, M; Moore, K
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 Monk, B; Tewari, K; Dubot, C; Caceres, M; Hasegawa, K; Shapira-Frommer, R; Salman, P; Yañez, E; Gümüş, M; Hurtado de Mendoza, M; Samouëlian, V; Castonguay, V; Arkhipov, A; Tekin, C; Li, K; Martin Nguyen, A; Monberg, M; Colombo, N; Lorusso, D
Endometrial carcinosarcoma
2023 Bogani, G; Ray-Coquard, I; Concin, N; Ngoi, N; Morice, P; Caruso, G; Enomoto, T; Takehara, K; Denys, H; Lorusso, D; Coleman, R; Vaughan, M; Takano, M; Provencher, D; Sagae, S; Wimberger, P; Póka, R; Segev, Y; Kim, S; Kim, J; Candido Dos Reis, F; Ramirez, P; Mariani, A; Leitao, M; Makker, V; Abu-Rustum, N; Vergote, I; Zannoni, G; Tan, D; Mccormack, M; Paolini, B; Bini, M; Raspagliesi, F; Benedetti Panici, P; Di Donato, V; Muzii, L; Colombo, N; Pignata, S; Scambia, G; Monk, B
Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994
2023 Kenter, G; Greggi, S; Vergote, I; Katsaros, D; Kobierski, J; van Doorn, H; Landoni, F; van der Velden, J; Reed, N; Coens, C; van Luijk, I; Colombo, N; Steen-Banasik, E; Ottevanger, N; Casado, A
Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence
2023 Plett, H; Ricciardi, E; Vacaru, V; Ramspott, J; Colombo, N; Sehouli, J; du Bois, A; Garbi, A; Richter, R; Ataseven, B; Aletti, G; Braicu, E; Heitz, F; Portuesi, R; Muallem, M; Dagres, T; Parma, G; Roser, E; Traut, A; Multinu, F; Harter, P
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
2023 Pignata, S; Oza, A; Hall, G; Pardo, B; Madry, R; Cibula, D; Klat, J; Montes, A; Glasspool, R; Colombo, N; Pete, I; Herrero Ibáñez, A; Marín, M; Ilieva, R; Timcheva, C; Di Maio, M; Blakeley, C; Taylor, R; Barnicle, A; Clamp, A
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice
2023 Lorusso, D; Colombo, N; Herraez, A; Santin, A; Colomba, E; Miller, D; Fujiwara, K; Pignata, S; Baron-Hay, S; Ray-Coquard, I; Shapira-Frommer, R; Kim, Y; Mccormack, M; Massaad, R; Nguyen, A; Zhao, Q; Mckenzie, J; Prabhu, V; Makker, V
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
2023 Schram, A; Colombo, N; Arrowsmith, E; Narayan, V; Yonemori, K; Scambia, G; Zelnak, A; Bauer, T; Jin, N; Ulahannan, S; Colleoni, M; Aftimos, P; Donoghue, M; Rosen, E; Rudneva, V; Telli, M; Domchek, S; Galsky, M; Hoyle, M; Chappey, C; Stewart, R; Blake-Haskins, J; Yap, T
Matrix Gla Protein drives stemness and tumor initiation in ovarian cancer
2023 Nieddu, V; Melocchi, V; Battistini, C; Franciosa, G; Lupia, M; Stellato, C; Bertalot, G; Olsen, J; Colombo, N; Bianchi, F; Cavallaro, U
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
2023 Makker, V; Colombo, N; Herráez, A; Monk, B; Mackay, H; Santin, A; Miller, D; Moore, R; Baron-Hay, S; Ray-Coquard, I; Ushijima, K; Yonemori, K; Kim, Y; Guerra Alia, E; Sanli, U; Bird, S; Orlowski, R; Mckenzie, J; Okpara, C; Barresi, G; Lorusso, D
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile